The Filing Desk

Arcutis Biotherapeutics vs MannKind

Arcutis Biotherapeutics ARQT · MannKind MNKD · Pharmaceuticals

Arcutis Biotherapeutics reported revenue of $376 million in fiscal 2025, about the same as MannKind's $349 million in fiscal 2025. Arcutis Biotherapeutics' revenue grew 91.3% in its latest year, and MannKind's grew 22.2%. Arcutis Biotherapeutics had an operating margin of -3.2%, against 11.1% at MannKind. Free cash flow was −$6 million at Arcutis Biotherapeutics and $14 million at MannKind.

Side by side

Arcutis BiotherapeuticsMannKind
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$376M$349M
Revenue growth91.3%22.2%
Revenue growth a year, last 5 years—39.9%
Gross margin90.2%92.3%
Operating margin−3.2%11.1%
Net margin−4.3%1.7%
Free cash flow−$6M$14M
Free cash flow margin−1.7%3.9%
Return on capital−16.9%—
Net debt to EBITDA—3.6x
Dividends and buybacks$0M$0M
Change in diluted share count5.2%10.7%
Last close$28.26$4.13
P/E at the last close134.6×—
Insider trades, last 12 monthssold $12.2 million—
Piotroski F-score4 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Arcutis BiotherapeuticsMannKind
Operating margin
Percent of revenue
Arcutis BiotherapeuticsMannKind
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arcutis BiotherapeuticsMannKind

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arcutis Biotherapeutics and MannKind pages.